Statement of Changes in Beneficial Ownership (4)
01 Junho 2021 - 7:55PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Barrage Khalil |
2. Issuer Name and Ticker or Trading Symbol
Protagenic Therapeutics, Inc.new
[
PTIX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
|
|
(Last)
(First)
(Middle)
149 FIFTH AVE,, SUITE 500 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
5/26/2021 |
|
(Street)
NEW YORK, NY 10010
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| PTIX Common stock NSO Options | $3.65 (1) | 5/26/2021 | | A | | 180000 (2) | | (3) | 5/26/2031 | PTIX common stock, Par Value $0.000001 | 180000 (2) | $0.00 | 180000 | D | |
| Explanation of Responses: |
| (1) | This exercise price was determined by the Board of Directors at a Board Meeting held May 26, 2021. |
| (2) | This number of options was determined by the Board of Directors at a Board Meeting held May 26, 2021. |
| (3) | The options are fully vested. |
Remarks:
Ex. 24, Power of Attorney |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Barrage Khalil
149 FIFTH AVE,
SUITE 500
NEW YORK, NY 10010 | X |
|
|
|
Signatures
|
| /s/ Alexander Arrow, as attorney-in-fact | | 6/1/2021 |
| **Signature of Reporting Person | Date |
Protagenic Therapeutics (NASDAQ:PTIX)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Protagenic Therapeutics (NASDAQ:PTIX)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
